StockData
CalciMedica, Inc. logo

CalciMedica, Inc. (CALC) stock

CALCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$1.22+0.03 (+2.52%)

Close on Nov 17, 2026Market cap $41.65MP/E –Yield –

CalciMedica r&d expenses

Research and development expenses are spending on new products and technology.

CalciMedica's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.55M, down 19.9% year over year. For fiscal 2025 it was $15.23M, up 5.2% from the year before. The highest annual figure on record is $30.58M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$15.23M+5.2%
FY2024Dec 31, 2024$14.48M-8.7%
FY2023Dec 31, 2023$15.86M+89.9%
FY2022Dec 31, 2022$8.35M-55.8%
FY2021Dec 31, 2021$18.90M-9.8%
FY2020Dec 31, 2020$20.96M-31.5%
FY2019Dec 31, 2019$30.58M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.10M-48.1%
Q1 FY2026Mar 31, 2026$3.49M-17.5%
Q4 FY2025Dec 31, 2025$3.11M-18.9%
Q3 FY2025Sep 30, 2025$3.85M+8.6%
Q2 FY2025Jun 30, 2025$4.05M-2.5%
Q1 FY2025Mar 31, 2025$4.22M+43.5%
Q4 FY2024Dec 31, 2024$3.83M+37.7%
Q3 FY2024Sep 30, 2024$3.55M+27.9%
Q2 FY2024Jun 30, 2024$4.16M+9.0%
Q1 FY2024Mar 31, 2024$2.94M-54.6%
Q4 FY2023Dec 31, 2023$2.78M+23.2%
Q3 FY2023Sep 30, 2023$2.77M-5.2%
Q2 FY2023Jun 30, 2023$3.81M-10.6%
Q1 FY2023Mar 31, 2023$6.49M+61.4%
Q2 FY2022Jun 30, 2022$2.26M-45.8%
Q1 FY2022Mar 31, 2022$2.93M-54.6%
Q4 FY2021Dec 31, 2021$4.27M-22.2%
Q3 FY2021Sep 30, 2021$4.02M-15.5%
Q2 FY2021Jun 30, 2021$4.17M-10.1%
Q1 FY2021Mar 31, 2021$6.45M+6.0%
Q4 FY2020Dec 31, 2020$5.49M-31.5%
Q3 FY2020Sep 30, 2020$4.76M-43.4%
Q2 FY2020Jun 30, 2020$4.63M–
Q1 FY2020Mar 31, 2020$6.09M–
Q4 FY2019Dec 31, 2019$8.01M–
Q3 FY2019Sep 30, 2019$8.40M–

More CalciMedica figures

See a number that looks wrong?